Research work · 2002
Bosentan Therapy for Pulmonary Arterial Hypertension
New England Journal of Medicine
Abstract
Endothelin, a peptide produced primarily by vascular endothelial cells, was discovered in 1980 and it was characterized as a powerful vasoconstrictor and mitogen for smooth muscle. Endothelin binds to two types of receptors, ETA and ETB. Activation of ETA and ETB receptors on smooth muscle cells mediates the vasoconstrictive and mitogenic effects of endothelin. In patients with pulmonary hypertension, endothelin plasma levels are elevated and the increase is correlated with right atrial pressure, pulmonary artery oxygen saturation and pulmonary vascular resistance. Bosentan is an oral active dual ETA and ETBreceptor antagonist. Bosentan therapy has improved symptoms, exercise capacity, hemodynamics, echocardiographic parameters and the outcome of patients with severe pulmonary hypertension. This review is focus on the role of bosentan therapy in pulmonary hypertension and the review of current literature.